Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T5JS
|
|||
| Former ID |
DIB009475
|
|||
| Drug Name |
TT-100
|
|||
| Synonyms |
TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct
Click to Show/Hide
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Company |
TriAct Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021633) | |||
| REF 2 | BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.